Evidence map›Paper›PMID 37676038›Full record

ArticleMicrobiology spectrum2023

A tool for the cheap and rapid screening of SARS-CoV-2 variants of concern (VoCs) by Sanger sequencing.

Germán Burgos, Andrés Ambuludí, USFQ SARS-CoV-2 Consortium, Diana Morales-Jadán, Miguel Angel Garcia-Bereguiain, Claire Muslin, Vinicio Armijos-Jaramillo

Abstract read
In one paragraph

Article in Microbiology spectrum, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Germán BurgosFacultad de Medicina, Universidad de Las Américas (UDLA) , Quito, Ecuador.ORCID 0000-0002-8400-2753
Andrés AmbuludíCarrera de Ingeniería en Biotecnología, Facultad de Ingenierías y Ciencias Aplicadas, Universidad de Las Américas (UDLA) , Quito, Ecuador.
USFQ SARS-CoV-2 ConsortiumInstituto de Microbiología, Colegio de Ciencias Biológicas y Ambientales (COCIBA), Universidad San Francisco de Quito (USFQ) , Cumbaya, Ecuador.
Diana Morales-JadánOne Health Research Group, Faculty of Health Sciences, Universidad de Las Américas (UDLA) , Quito, Ecuador.ORCID 0000-0002-2013-4132
Miguel Angel Garcia-BereguiainOne Health Research Group, Faculty of Health Sciences, Universidad de Las Américas (UDLA) , Quito, Ecuador.ORCID 0000-0003-0025-3609
Claire MuslinOne Health Research Group, Faculty of Health Sciences, Universidad de Las Américas (UDLA) , Quito, Ecuador.ORCID 0000-0002-2746-6914
Vinicio Armijos-JaramilloCarrera de Ingeniería en Biotecnología, Facultad de Ingenierías y Ciencias Aplicadas, Universidad de Las Américas (UDLA) , Quito, Ecuador.ORCID 0000-0003-2965-2515

Funding

HHS | NIH | OSC | Common Fund (NIH Common Fund) 2022001Red para el desarrollo de instrumentos innovadores aplicados a la investigación epidemiologica en América Latina 2022001United States Agency for International Development (USAID) 2022001Universidad de Las Américas Ecuador (UDLA) BIO.TPA.20.03Universidad de Las Américas Ecuador (UDLA) MED.GBF.20.06Universidad de Las Américas Ecuador (UDLA) MED.NK.20.10
6 · The paper itself

Abstract

importanceOur work describes a new (Sanger sequencing-based) screening methodology for SARS-CoV-2, performing PCR amplifications of a few target regions to detect diagnostic mutations between virus variants. Using the methodology developed in this work, we were able to discriminate between the following VoCs: Alpha, Beta, Gamma, Delta, and Omicron (BA.1/BA.1.1, BA.2, BA.3, BA.4, and BA.5). This becomes important, especially in low-income countries where current methodologies like next-generation sequencing have prohibitive costs. Furthermore, rapid detection would allow sanitary authorities to take rapid measures to limit the spread of the virus and therefore reduce the probability of new virus dispersion. With this methodological approach, 13 previously unreported diagnostic mutations among several Omicron lineages were found.

Indexed as

Omicron lineagesreceptor-binding domainSanger sequencingSARS-CoV-2SARS-CoV-2 surveillancevariant of concern (VoC)

Identifiers

PMID37676038
PMCPMC10586709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.